Shares of Cryolife Inc (NYSE:CRY) have earned an average rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $23.63.
Several equities analysts have commented on CRY shares. Canaccord Genuity reissued a “buy” rating and set a $25.00 price objective on shares of Cryolife in a research report on Monday, October 9th. Zacks Investment Research raised Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Northland Securities reaffirmed a “buy” rating and issued a $23.50 price target on shares of Cryolife in a research report on Monday, November 13th. TheStreet lowered Cryolife from a “b” rating to a “c+” rating in a research report on Monday, October 30th. Finally, Lake Street Capital lifted their price target on Cryolife to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, October 11th.
In other news, CAO Amy Horton sold 4,000 shares of Cryolife stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $76,000.00. Following the completion of the transaction, the chief accounting officer now owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP David C. Gale sold 20,000 shares of Cryolife stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $19.63, for a total value of $392,600.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,190 shares of company stock valued at $1,138,240. 6.00% of the stock is owned by insiders.
Shares of Cryolife (NYSE:CRY) traded up $0.10 during trading on Friday, reaching $18.45. The company’s stock had a trading volume of 86,991 shares, compared to its average volume of 109,000. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90. The stock has a market capitalization of $613.95, a price-to-earnings ratio of 65.89 and a beta of 0.82. Cryolife has a fifty-two week low of $14.02 and a fifty-two week high of $24.00.
Cryolife (NYSE:CRY) last announced its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. The business had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. Cryolife had a return on equity of 6.43% and a net margin of 5.28%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.13 earnings per share. equities analysts expect that Cryolife will post 0.28 EPS for the current year.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.